Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Exact Prediction of Various Anticancer Medication Efficacy Using Multi Target Regression and Support Vector Regression Analysis

Germano Almeida

Cancer remains a significant global health concern, and the development of effective anticancer medications is crucial for improving patient outcomes. However, predicting the efficacy of different anticancer drugs is a complex task due to the heterogeneity of cancer and the multifactorial nature of drug response. In this study, we propose a novel approach that combines multi-target regression and support vector regression analysis to accurately predict the efficacy of various anticancer medications. The selection of appropriate anticancer medications for individual patients is a challenging task. While several predictive models have been developed, most of them focus on single drugs and fail to capture the intricate relationships between multiple drugs and their targets. To overcome these limitations, we present a comprehensive framework that utilizes multi-target regression and support vector regression analysis for precise prediction of anticancer medication efficacy. To further enhance the predictive performance, we integrate support vector regression analysis into our framework. Support vector regression is a powerful machine learning algorithm that can effectively handle high-dimensional datasets and nonlinear relationships. It allows us to build robust models that can accurately predict anticancer medication efficacy.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.